Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Sep 4;6(9):ofz235.
doi: 10.1093/ofid/ofz235. eCollection 2019 Sep.

Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report

Jessica Howard-Anderson  1 , Stephanie M Pouch  1 , Mary Elizabeth Sexton  1 , Aneesh K Mehta  1 , Andrew L Smith  2 , George M Lyon 3rd  1 , Rachel Friedman-Moraco  1
Affiliations
Case Reports

Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report

Jessica Howard-Anderson et al. Open Forum Infect Dis. .

Abstract

Left ventricular assist device infections (LVADIs) are common but challenging to treat, often requiring prolonged courses of intravenous antibiotics. Dalbavancin could have a role in treating patients with chronic LVADIs given its less frequent dosing requirements. Here, we illustrate a case in which dalbavancin was used as suppressive therapy for an LVADI for greater than 7 months.

Keywords: Staphylococcus aureus; dalbavancin; left ventricular assist devices.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Timeline of Significant Events. MRSA indicates methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; TMP/SMX, trimethoprim/sulfamethoxazole.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Nienaber JJ, Kusne S, Riaz T, et al. ; for the Mayo Cardiovascular Infections Study Group Clinical manifestations and management of left ventricular assist device-associated infections. Clin Infect Dis 2013; 57:1438–48. - PMC - PubMed
    1. McCarthy FH, Kobrin D, Rame JE, et al. . Increasing frequency of left ventricular assist device exchanges in the United States. Ann Thorac Surg 2015; 100:1660–4; discussion 1665. - PubMed
    1. Pfaller MA, Mendes RE, Duncan LR, et al. . Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. J Antimicrob Chemother 2018; 73:2748–56. - PubMed
    1. Boucher HW, Wilcox M, Talbot GH, et al. . Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370:2169–79. - PubMed
    1. Dunne MW, Puttagunta S, Giordano P, et al. . A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis 2016; 62:545–51. - PMC - PubMed

Publication types